

Nucleobase Derivatives as Building Blocks to Form Ru(II)-Based Complexes with High Cytotoxicity

Diogo E. L. Carvalho,^{†,||} Katia M. Oliveira,^{†,||} Larissa M. Bomfim,[‡] Milena B. P. Soares,[‡] Daniel P. Bezerra,^{‡,§} Alzir A. Batista,[§] and Rodrigo S. Correa^{*,†,§}


[†]Departamento de Química, Instituto de Ciências Exatas e Biológicas—Campus Morro do Cruzeiro, Universidade Federal de Ouro Preto—UFOP, CEP 35400-000 Ouro Preto, MG, Brazil

[‡]Fundação Oswaldo Cruz, Gonçalo Moniz, Rua Waldemar Falcão, 121, Candeal, CEP 40296-710 Salvador, BA, Brazil

[§]Departamento de Química, Universidade Federal de São Carlos—UFSCar, Rod. Washington Luís, km 235 - SP-310, CEP 13565-905 São Carlos, SP, Brazil

Supporting Information

ABSTRACT: Two new Ru(II)-based complexes containing 2-thiouracil derivatives, known as 2-thiouracil (2TU) and 6-methyl-2-thiouracil (6m2TU), were synthesized using *cis,trans*-[RuCl₂(PPh₃)₂(bipy)] as a precursor. The obtained compounds with a general formula *trans*-[Ru(2TU)(PPh₃)₂(bipy)]PF₆ (**1**) and *trans*-[Ru(6m2TU)(PPh₃)₂(bipy)]PF₆ (**2**) were characterized by analytical techniques such as NMR, UV–vis, and IR spectroscopies, elementary analysis, mass spectrometry, and single-crystal X-ray diffraction. Moreover, the investigation of the complexes–DNA interaction were carried out using spectrophotometric titrations and showed that the complexes present a weak interaction with this biomolecule. The compounds were evaluated against HL-60, K-562, HepG2, and B16-F10 cancer cells and against noncancer cells (PBMCS). The results of the biological assay revealed that complex **2** is more promising than complex **1**. Finally, the present study suggests that complexes **1** and **2** causes cell death by apoptosis, significantly increasing the percentage of apoptotic HL-60 cells, in which the compounds altered the cell cycle, reducing the cells in G₁/G₀, G₂/M, and S phases.



INTRODUCTION

Uracil is a well-known pyrimidine nucleobase used as an RNA building block. Pyrimidines and purine derivatives comprise an important molecular framework to drug design, in which structural modifications on nucleobase derivatives can lead to the formation of compounds with pharmacological properties.^{1,2} An example involving purine is 6-mercaptopurine (6-MP), an antineoplastic drug that acts as an antimetabolite agent.^{3,4} Concerning the uracil moiety, a widely studied compound called 5-fluorouracil (SFU) has also been used as an anticancer drug.^{5,6} Besides the molecular modification in the molecule ring, special attention has been directed toward the coordination of 5-fluorouracil and derivatives with transition metals.^{7–9} As a consequence, many compounds containing these classes of molecules have been obtained to exhibit different physicochemical properties, and thus able to alter the effectiveness of the drug.^{10–13} Therefore, from the coordination point of view, several strategies in preparative inorganic chemistry have been widely investigated to coordinate a bioligand with a metal center to increase their biological potential.^{14–16}

Recently, we have reported structural and biological studies with cationic Ru(II)-thymine and Ru(II)-5-fluorouracil complexes, and their promising properties such as metallodrug candidates, with high cytotoxic against cancer cells, have led to further studies *in vivo*.⁸ Moreover, neutral ruthenium(II)-

based complexes containing two 2-thiouracil derivative ligands per metal center have been recently investigated, presenting promising results, mainly against leukemia HL-60 cells.¹⁷ Goitia and co-workers have reported that gold(I)/complex with 2-thiouracil exhibits excellent cytotoxic activity against PC-12 and NIH-3T3 cell lines.¹⁸ Thus, having in mind that Ru(II) complexes have been investigated in the development of compounds with anticancer properties, to evaluate the structural modification on biological properties of ruthenium complexes with 2-thiouracil derivatives, we present here the synthesis of two new monocationic complexes, expecting that they will have good cytotoxicity against cancer cells.^{19–24}

RESULTS AND DISCUSSION

To obtain the desired complexes studied here, *cis,trans*-[RuCl₂(PPh₃)₂(bipy)] was used as precursor, which was obtained following the procedures described by Batista and co-workers.²⁵ The synthetic route of complexes **1** and **2** is represented in Scheme 1.

Given that there are few studies of ruthenium(II)-based complexes containing 2-thiouracil derivatives, the study of a new class of compound was performed. Owing to fact that

Received: June 26, 2019

Accepted: December 17, 2019

Published: January 3, 2020

6m2TU present the $\nu\text{C}=\text{O}$ stretching vibration at 1711 (for 2TU) and 1674 cm^{-1} (for 6m2TU), whereas in compounds **1** and **2**, the values found are 1657 and 1651 cm^{-1} . Furthermore, all compounds present bands of $\nu\text{C}=\text{N}$ of the bipy and 2TU/6m2TU ligands. Analyzing the region of the spectrum in the range of 1400 to 1600 cm^{-1} , it can be observed that in all complexes, signals at 1433 and 1481 cm^{-1} are present, which can be attributed to $\nu\text{C}=\text{C}$ stretching vibrations. Compared with the precursor complex, it can be seen that in the 1536 cm^{-1} region, there is a common band, which refers to the $\nu\text{C}=\text{N}$ stretching vibrations of the bipy ligand. Thus, it can be noted that in complexes **1** and **2**, there are bands that occur at 1570 cm^{-1} and these may correspond to the $\nu\text{C}=\text{N}$ stretching vibration of the thiouracil derivative ligands. The band at around 840 cm^{-1} due to the $\nu\text{P}-\text{F}$ stretching vibration confirms the presence of PF_6^- as a counterion.

In the present report, the molecular structures of complexes **1** and **2** were determined by single-crystal X-ray diffraction (Figure 1 and Table S1). The main bond lengths obtained for **1** and **2** (Table S2) reveal that the Ru–L bond values, around the metal center, are similar in both complexes. This behavior is expected given that the stereochemistry is the same as that of the phosphorus atoms of the PPh_3 ligand trans to each one.




Figure 1. Crystal structures of complexes **1** and **2**.

The nitrogen atoms of the bipy, labeled as N2 and N4, are trans to N3 and S2 atoms of thiouracil ligands, respectively. The X-ray diffraction results show that 2TU and 6m2TU are coordinated by the nitrogen atom N3 and sulfur, as bidentate. Mainly, in complex **2**, the coordination involving the N3 atom contribute to decreasing the steric hindrance around the methyl group of position 6, in 6m2U. Interestingly, both complexes present intramolecular interactions between the C–H of the bipy ligand and the oxygen atom of the ligand 2-thiouracil derivative [$\text{C}-\text{H}(\text{bipy})\cdots\text{O4}$]. This behavior is important to stabilize the molecular structure of the complexes, allowing the coordination to occur through the N3 atom. As can be seen in Figure 1, the coordination involving the N1 atom and S2 atom will result in a steric hindrance between the $\text{C}-\text{H}(\text{bipy})$ and the C–H of 2TU or the $-\text{CH}_3$ of 2TU, respectively.

The different coordinations of the 2TU and 6m2TU ligands in **1** and **2**, compared with those of the previously reported complexes $\text{cis}-[\text{Ru}(\text{PPh}_3)_2(\text{TU})_2]$,¹⁶ also contribute to the different intermolecular interaction patterns related to the $\text{cis}-[\text{Ru}(\text{PPh}_3)_2(\text{TU})_2]$ complexes. In the $\text{cis}-[\text{Ru}(\text{PPh}_3)_2(\text{TU})_2]$ complexes, there is a formation of a pattern of type $\text{R}_2^2(8)$ graph-set, forming dimeric bonds $\text{N}-\text{H}\cdots\text{O}$. On the other hand, the two crystal structures reported here present the molecules forming intermolecular interactions linking the molecules as a chain, $\text{C}_2^2(8)$ graph-set, involving the atoms $\text{N1}-\text{H}\cdots\text{O4}$ (Figure 2).




Figure 2. H-bonds forming an infinite $\text{N}-\text{H}\cdots\text{O}$ chain.

The structural aspects of complexes **1** and **2** may contribute to affecting their biological activity. In the CT-DNA binding study, by UV absorption titration, it was found that the intrinsic binding constant (K_b) values around $3.0\text{--}5.0 \times 10^3\text{ M}^{-1}$. These results suggested that complexes **1** and **2** interact weakly with DNA, compared with others complexes with thiouracil derivatives, as previously reported, which present more regions capable of carrying out hydrogen bonds, showing K_b constants at around 10^4 M^{-1} .¹⁷ Furthermore, the K_b values found are lower than those for complexes, which demonstrates the ability to intercalate DNA.^{29,30}

The cytotoxicity activities of compounds **1** and **2** were investigated against four cancer cells and one noncancer cell population (Table 1). Even though the IC_{50} values are similar for both compounds, complex **2** was more potent cytotoxic than complex **1**. Both complexes showed IC_{50} values for cancer cells comparable with the platinum metallodrug, oxaliplatin,

Table 1. IC₅₀ Values (μM) Obtained from the Cytotoxicity Assay and DNA Binding Constant (K_b) for Complexes 1 and 2^a

cells	hystotype	IC ₅₀ in μM			
		1	2	oxaliplatin	doxorubicin
cancer cells					
HL-60	human promyelocytic leukemia	2.33	1.65	0.45	0.09
		1.38–3.94	1.09–2.48	0.34–1.06	0.04–0.15
K-562	human chronic myelocytic leukemia	2.75	2.12	1.30	0.15
		1.88–4.05	1.40–3.20	0.46–2.12	0.05–0.23
HepG2	human hepatocellular carcinoma	12.31	9.13	1.00	0.02
		8.10–18.71	6.86–12.14	0.36–2.25	0.01–0.05
B16-F10	melanoma	5.28	3.07	0.07	0.02
		3.55–7.84	2.09–4.52	0.04–0.09	0.01–0.06
noncancer cells					
PBMC	human peripheral blood mononuclear cells	6.99	3.91	8.45	2.45
		3.68–13.25	2.26–6.78	4.53–13.47	1.35–4.45
DNA binding constant					
K _b (10 ³ M ⁻¹)		5.0 ± 1.1	3.0 ± 1.0		

^aIC₅₀ (μM) were obtained by nonlinear regression from three independent experiments that were executed in duplicate, using Alamar blue assay after 72 h incubation. DNA binding constants are presented as mean ± S.D.

and doxorubicin (see Table 1). The free ligands 2TU and 6m2TU were not cytotoxic at the concentrations investigated.

As shown in Table 2, complexes 1 and 2 presented more selectivity to HL-60 (3 times more cytotoxicity in relation to

Table 2. Selectivity Index (SI) of Complexes 1 and 2^a

cancer cells	noncancer cell			
	PBMC			
	1	2	OXA	DOX
HL-60	3.0	2.37	18.78	27.22
K-562	2.5	1.84	6.5	16.33
HepG2	0.57	0.43	8.45	122.5
B16-F10	1.32	1.27	120.7	122.5

^aSelectivity index (SI) of complexes was determined by the relation of IC₅₀ values: SI = IC₅₀ [noncancer cells]/IC₅₀ [cancer cells]. Cancer cells: HL-60 (human acute promyelocytic leukemia); K-562 (human chronic myelogenous leukemia); HepG2 (human hepatocellular carcinoma); and B16-F10 (mouse melanoma). Noncancer cells: PBMC (human peripheral blood mononuclear cells). Doxorubicin (DOX) and oxaliplatin (OXA) were used as positive controls.

PBMC for complex 1 and 2.37 times more cytotoxicity in relation to PBMC for complex 2) when compared with the other cancer cells (K562, HepG2, and B16-F10).

Next, we examined light-scattering features, annexin V-FITC/PI staining, and intracellular DNA content of HL-60 cells after incubation with complexes 1 (1 and 2 μM) and 2 (0.5 and 1 μM) by flow cytometry. Both complexes caused cell shrinkage, as observed by reduction in forward light scatter (FSC), and nuclear condensation, as observed by increase in side scatter (SCC), both morphological changes characteristic of apoptotic cells (Figure 3). In addition, augments in the percentage of early apoptotic cells was found in HL-60 cells treated with both complexes ($P < 0.05$) (Figure 4). Complex 1 induced early apoptotic cells in 40.5 and 49.8%, while 36.5 and 41.7% were found after the treatment with complex 2 at the lowest and highest concentrations, respectively. Doxorubicin (1 μM) caused early apoptotic cells in 35.4% against 8.1% observed in the negative control. Both complexes also caused a significant internucleosomal DNA fragmentation in HL-60 cells after 24 h incubation ($P < 0.05$) (Figure 5). Complex 1

increased the DNA fragmentation to 71.4 and 94.0% and complex 2 increased it to 47.2 and 67.9%, at lowest and highest concentrations, respectively. Doxorubicin (1 μM) increased the DNA fragmentation up to 59.7%, and 18.6% was observed for negative control cells. The cell cycle phases, G₁/G₀, S, and G₂/M, were reduced proportionally.

CONCLUSIONS

In summary, two new Ru(II) complexes [1 and 2] containing thiouracil derivatives were synthesized and studied against cancer cells. Complexes 1 and 2 are cationic, presenting the two triphenylphosphine ligands in the trans configuration to each other, such as suggested by the ³¹P{¹H} NMR experiments. The thiouracil ligand presents the sulfur atom and N3 atom trans to N4 and N2 nitrogen of bipyridine, respectively. The complex/DNA binding studied reveals the K_b of about 10³ M⁻¹, revealing a weak DNA interaction. The IC₅₀ values against cancer cells for complexes 1 and 2 are lower than the IC₅₀ values against noncancer cells that are desired. The complex 2 with 6m2TU ligand showed a higher potency than the complex 1 with 2TU ligand. Both Ru(II) compounds caused DNA fragmentation, leading cell death by apoptosis. Complexes 1 and 2 also altered the cell cycle, reducing the cells in G₁/G₀, S, and G₂/M phases.

EXPERIMENTAL SECTION

Synthesis of the Complexes. Synthesis of *trans*-[Ru(2TU)(PPh₃)₂(bipy)]PF₆ (1) and *trans*-[Ru(6m2TU)(PPh₃)₂(bipy)]PF₆ (2). To the reactional media, 0.19 mmol of 2TU (24 mg) or 6m2TU (27 mg) ligands, in methanol (20 mL), and with 20 μL of triethylamine was added using a Schlenk flask. After ligand solubilization, 150 mg (0.18 mmol) of the complex precursor, [RuCl₂(PPh₃)₂(bipy)], dissolved in 80 mL of CH₂Cl₂ solvent was added to the Schlenk flask. The reactional systems were kept under reflux and stirring for about 12 h. After that, the volume of the solution was reduced to ca. 2 mL, and the orange solid was precipitated by water. The final products 1 and 2 were collected by filtration, washed with hot water, diethyl ether, and dried under vacuum. Yield 135 mg (73%) for compound 1 and 150 mg (80%) for compound 2.




Figure 3. Effect of complexes **1** and **2** in HL-60 cell morphology, as determined by light-scattering features detected by flow cytometry after 24 h incubation. Negative control (CTL) was treated with vehicle (0.1% DMSO), and doxorubicin (DOX, 1 μM) was used as a positive control. Data are presented as representative flow cytometric dot plots of three independent experiments performed in duplicate. Ten thousand events were evaluated per experiment, and cellular debris omitted from analysis.

Complex 1. Molar conductance ($\Omega^{-1} \text{cm}^2 \text{mol}^{-1}$, CH_2Cl_2) 50.1. Anal. calcd for $[\text{RuC}_{50}\text{H}_{41}\text{F}_6\text{N}_4\text{OSP}_3]$: exp. (calcd) C 56.68(56.87); H 4.37(4.10), N 5.23(5.31); S 2.78(3.04) %. IR (cm^{-1}): 3202, 3115, 3078, 3057, 2957, 2924, 2854, 1657, 1636, 1605, 1585, 1539, 1481, 1433, 1275, 1190, 1159, 1090, 1026, 1001, 841, 760, 744, 717, 696, 619, 557, 519, 403, 353. $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, $\text{DMSO}-d_6$, 298 K) δ (ppm): 32.165 (s); ^1H NMR (400 MHz, $\text{DMSO}-d_6$, 298 K) δ (ppm): 12.16 (H, N–H of 2TU); 11.49 and 10.64 (2H, C–H of bipy near the coordinated nitrogen atoms); 8.00–7.50 (6H atoms of bipy) 6.7 (H, C_6 –H of 2TU); 5.2 (H, C_5 –H of 2TU). $^{13}\text{C}\{^1\text{H}\}$ NMR (125.74 MHz, $\text{DMSO}-d_6$, 298 K) δ (ppm): 176.5 (C=S); 171.5 (C=O); 156.2 (C6 of 2TU), 106.2 (C5 of 2TU); 158.20–157.56, 137.0–122.3 (C–bipy, C– PPh_3). UV–vis (DMSO , $5 \times 10^{-5} \text{M}$): λ/nm ($\epsilon/\text{M}^{-1} \text{cm}^{-1}$) 300 (30 000), 336 (15 500), 450 (6000).

Complex 2. Molar conductance ($\Omega^{-1} \text{cm}^2 \text{mol}^{-1}$, CH_2Cl_2) 58.4. Anal. calcd for $[\text{RuC}_{51}\text{H}_{43}\text{F}_6\text{N}_4\text{OSP}_3]$: exp. (calcd): C 57.55(57.25), H 4.60(4.24), N 5.33(5.24), S 2.89(3.00) %. IR (cm^{-1}) 3207, 3117, 3076, 3057, 2958, 2924, 2854, 2795, 1651, 1618, 1605, 1572, 1537, 1481, 1433, 1470, 1365, 1309, 1273, 1221, 1184, 1159, 1090, 1072, 1028, 999, 843, 764, 744, 698, 613, 557, 519, 403, 351. $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, $\text{DMSO}-d_6$, 298 K): δ (ppm) 32.161 (s); ^1H NMR (400 MHz, $\text{DMSO}-d_6$, 298 K) δ (ppm): 11.3 (H, N–H), 10.6 and 9.2 (2H, C–H of bipy near the coordinated nitrogen atoms); 8.00–7.00 (30H of PPh_3 ligands and 6H aromatic hydrogen atoms of bipy); 5.05 (H, C_5 –H of 6m2TU); 1.6 (3H, CH_3 of 6m2TU). $^{13}\text{C}\{^1\text{H}\}$ NMR (125.74 MHz, $\text{DMSO}-d_6$, 298 K) δ (ppm): 176.1 (C=S); 171.4 (C=O); 158.4–122.2 (1C at position 6 of 6m2TU, 10C of bipy, 36C of PPh_3 ligands), 105.2 (1C at position 5 of 6m2TU), 16.6 (1C of the methyl group of 6m2TU). UV–vis (DMSO , $1.8 \times 10^{-5} \text{M}$): λ/nm ($\epsilon/\text{M}^{-1} \text{cm}^{-1}$) 300 (34 000), 338 (13 100), 452 (7010).

Physical Measurements and Materials. The commercial reagents were of grade or comparable purity and used as supplied. The compounds used here, CT-DNA, Tris–HCl,

Tris-base, oxaliplatin, PPh_3 , bipy, 2TU, 6m2TU, and $\text{RuCl}_3 \cdot 3\text{H}_2\text{O}$, were acquired from Sigma-Aldrich (St. Louis, MO). Elementary analyses were carried out on an EA 1108 FISON Instruments CHNS microanalyzer. High-resolution mass spectra (HRMS) of complexes **1** and **2** were obtained in a MicroToF-Q II Bruker Daltonics Mass Spectrometer (Le) in the positive-ion mode, using methanol/acetonitrile as solvents (LC/MS grade from Honeywell/B&J Brand). Conductivity values were determined using 10^{-3}M solutions of the complexes in CH_2Cl_2 employing a MeterLab CDM2300 instrument. In addition, the IR spectra were obtained, in CsI, on a FT-IR Bomem-Michelson 102 spectrometer in the 4000–200 cm^{-1} region. Cyclic voltammetry (CV) experiments were carried out using an electrochemical analyzer BAS, model 100B at room temperature. For that, an CH_2Cl_2 solution containing 0.10 $\text{mol L}^{-1} \text{Bu}_4\text{NClO}_4$ (TBAP) as a supporting electrolyte was employed and an one-compartment cell, with both working and auxiliary electrodes as stationary Pt foils, and Ag/AgCl as the reference electrode, 0.10 M TBAP in CH_2Cl_2 , was employed. Under these conditions, the ferrocene (Fc) is oxidized at 0.43 V (Fc+/Fc). All complexes were studied by NMR technique (^1H , $^{31}\text{P}\{^1\text{H}\}$, and ^{13}C NMR). All spectra were obtained on a Bruker DRX 400 MHz, using tetramethylsilane (TMS) as an internal reference and solvent $\text{DMSO}-d_6$ to the two compounds. The $^{31}\text{P}\{^1\text{H}\}$ chemical shifts were reported based on H_3PO_4 85% reference. All of the spectra obtained here are represented in the Supporting Information (Figures S1–S25). The UV–vis spectra of complexes **1** and **2** were obtained on a Hewlett Packard diode array 8452A, using CH_2Cl_2 as a solvent. All single crystals of the Ru(II)-thiouracil-based complexes (**1** and **2**) were obtained at room temperature by the solvent diffusion method. We have used the diffusion of diethyl ether to a complex solution ($\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$). Single-crystal X-ray diffraction experiments for both complexes were carried out at room temperature on an Enraf–Nonius Kappa-CCD diffractometer using the Mo $\text{K}\alpha$ radiation ($\lambda = 0.71073 \text{ \AA}$)




Figure 4. Effect of complexes **1** and **2** on apoptosis induction in HL-60 cells, as determined by flow cytometry using annexin V-FITC/propidium iodide staining after 24 h incubation. (A) Representative flow cytometric dot plots. (B) Quantification of viable (annexin V-FITC/PI double negative cells), early apoptosis (annexin V-FITC positive, but PI negative cells), late apoptosis (annexin V-FITC/PI double positive cells), and necrosis cells (PI positive, but annexin V-FITC negative cells). Negative control (CTL) was treated with vehicle (0.1% DMSO), and doxorubicin (DOX, 1 μM) was used as positive control. Data are presented as mean ± S.E.M. of three independent experiments performed in duplicate. Ten thousand events were evaluated per experiment, and cellular debris omitted from analysis. * $P < 0.05$ compared with negative control by ANOVA, followed by Student–Newman–Keuls test.

monochromated by graphite. The crystal structures of **1** and **2** were solved by the direct method and refined using the SHELXS-97 and SHELXL-97 programs, respectively. Absorption corrections were carried out using the Gaussian method. All nonhydrogen atoms of complexes **1** and **2** were located and refined with anisotropic thermal parameters. The C–H aromatic hydrogen atoms were added with C–H distance fixed at 0.93 Å and refined with fixed displacement parameters [$U_{\text{iso}}(\text{H}) = 1.2 U_{\text{eq}}(\text{Csp}^2)$]. In complex **2**, the H-atoms of the methyl group were set as isotropic with the C–H distance of 0.96 Å and $U_{\text{iso}}(\text{H}) = 1.5 U_{\text{eq}}(\text{Csp}^3)$.

For structure representations, the MERCURY 4.0 program was used. In addition, we have used the CrystalExplorer program to access the Hirshfeld surfaces, allowing us to obtain the fingerprint plots for complexes **1** and **2**.

CT-DNA Binding Experiments. Spectroscopic Titrations. To study the DNA interaction by spectroscopic titrations, we

have used a DNA solution prepared in a Tris–HCl buffer at pH = 7.2 [0.5 mM Tris-base, 5 mM Tris–HCl, 50 mM NaCl]. The ration of UV absorbance at 260 and 280 nm indicated that the CT-DNA solution is protein-free. Thus, the concentration of CT-DNA was determined using the absorption intensity at 260 nm and the molar absorption coefficient value of $6600 \text{ M}^{-1} \text{ cm}^{-1}$. The ruthenium complexes **1** and **2** were solubilized in a Tris–HCl buffer containing DMSO at 5%. The UV–vis titration experiments were performed keeping the concentration of ruthenium complex fixed at 25 μM and increasing the concentrations of the CT-DNA. A sample correction was made for the absorbance of DNA and the spectra were recorded after solution equilibration for 2 min. The intrinsic equilibrium binding constant (K_b) of the complexes to CT-DNA was obtained using the expression of Wolfe and co-workers.³¹ Alterations in the absorption intensity with the




Figure 5. Effect of complexes 1 and 2 in the cell cycle distribution of HL-60 cells, as determined by flow cytometry using propidium iodide staining after 24 h incubation. (A) Representative flow cytometric histograms. (B) Quantification of sub-G₁ (internucleosomal DNA fragmentation), G₀/G₁, S, and G₂/M percentage distribution. Negative control (CTL) was treated with vehicle (0.1% DMSO), and doxorubicin (DOX, 1 µM) was used as a positive control. Data are presented as mean ± S.E.M. of three independent experiments performed in duplicate. Ten thousand events were evaluated per experiment, and cellular debris omitted from analysis. **P* < 0.05 compared with negative control by ANOVA, followed by the Student–Newman–Keuls test.

increasing concentration of CT-DNA was monitored and analyzed by regression analysis.

In Vitro Cytotoxicity Assay. HL-60 (human promyelocytic leukemia), K-562 (human chronic myelocytic leukemia), HepG2 (human hepatocellular carcinoma), and B16-F10 (mouse melanoma) cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA) and cultured following the instructions of ATCC animal cell culture guide. All cell lines were tested for mycoplasma by Lookout Mycoplasma qPCR detection kit (Sigma-Aldrich) and were mycoplasma free. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient in GE Ficoll-Paque Plus from heparinized blood collected from 20- to 35-year-old, nonsmoker healthy donors after obtaining an informed consent. PBMCs were cultured in RPMI 1640 medium plus 20% fetal bovine serum, 2 mM glutamine, and 50 µg/mL gentamycin at 37 °C with 5% CO₂. ConA (10 µg/mL) was added at the beginning of the culture and treated with

complexes 1 and 2 after 24 h incubation. Research Ethics Committee from the Fiocruz-BA approved the experimental protocol (number 031019/2013).

Cell viability was measured by alamar blue method, as previously described.³² Cells were plated into 96-well plates (0.7 × 10⁵ cells/mL for adherent cells or 0.3 × 10⁶ cells/mL for cells suspended in 100 µL of medium). After 24 h, complexes 1 and 2 were dissolved in DMSO to form a solution of 0.19–25.0 µg/mL. Then, the sample compounds were added to each well and kept incubated for a period of 72 h. Oxaliplatin (OXA) and DOX, doxorubicin hydrochloride, from Laboratory IMA S.A.I.C were used as positive controls. Four hours (for cell lines) or 24 h (for PBMC) before the end of incubation, 20 µL of a stock solution (0.312 mg/mL) of alamar blue (resazurin; from Sigma-Aldrich) was added to each well. Absorbance was measured using a SpectraMax 190 multiplate reader at 570 and 600 nm.

Flow Cytometric Assays. FITC Annexin V apoptosis detection kit I (BD Biosciences, San Jose, CA) was used for apoptosis quantification, and the analysis was performed according to manufacturer's instructions. Cell fluorescence and light scattering features were measured by flow cytometry. Percentages of viable (annexin V-FITC/PI double negative cells), early apoptotic (annexin V-FITC positive, but PI negative cells), late apoptotic (annexin V-FITC/PI double positive cells), and necrotic (PI positive, but annexin V-FITC negative cells) cells were quantified.

Internucleosomal DNA fragmentation and cell cycle distribution were analyzed by the quantification of DNA content.³³ Cells were harvested in a permeabilization solution containing 0.1% Triton X-100, 2 $\mu\text{g}/\text{mL}$ propidium iodide (PI), 0.1% sodium citrate, and 100 $\mu\text{g}/\text{mL}$ RNase (all from Sigma-Aldrich Co.) and incubated in dark for 15 min at room temperature. Cell fluorescence was determined by flow cytometry. In this assay, all DNA sub-diploid in size (sub- G_1/G_0) was considered internucleosomal DNA fragmentation, and G_1/G_0 , S, and G_2/M phases were quantified.

For all flow cytometry analyses, 10 000 events were recorded per sample using a BD LSRFortessa cytometer, BD FACSDiva software (BD Biosciences), and FlowJo software 10 (FlowJo Lcc; Ashland, OR). Cellular debris were omitted from the analysis.

Statistical Analysis. Data are presented as mean \pm S.E.M. or IC_{50} values [half-maximal inhibitory concentration], and their 95% confidence intervals calculated by nonlinear regression from three independent experiments evaluated in duplicate. Statistical analysis was carried out using the Intuitive Software for Science GRAPHPAD.

■ ASSOCIATED CONTENT

● Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsomega.9b01921>.

Crystallographic information files (CIFs) were deposited on the Cambridge Structural database [CCDC 1924442 (1) and CCDC 1924443 (2)]. These data can be obtained free of charge via <http://www.ccdc.cam.ac.uk/conts/retrieving.html> (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, U.K.; Fax: +44 1223 336033; E-mail: deposit@ccdc.cam.ac.uk); Figures S1–S6 ($^{31}\text{P}\{^1\text{H}\}$, $^{13}\text{C}\{^1\text{H}\}$, and ^1H NMR spectra for complexes 1 and 2); Figure S7 ^1H – ^1H COSY of complex 1; Figure S8 and S9 (HRMS spectra for complexes 1 and 2), S10 and S11 (IR spectra for compounds 1 and 2), S12 and S13 (electrochemical experiment for compounds 1 and 2), S14 (Hirshfeld surface and fingerprint plot for compounds 1 and 2), S15 (CT-DNA titration for compounds 1 and 2), S16 and S17 (UV–vis spectra in DMSO for complexes 1 and 2), S18 ($^{31}\text{P}\{^1\text{H}\}$ NMR spectra of complex 1 and complex 2 after 24 h of incubation in DMSO), and S19 (^1H NMR signal integrations for complexes 1 and 2); Table S1 (X-ray data collections and refinement details for complexes 1 and 2); Table S2 (Infrared assignment for complexes 1 and 2) (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: rodrigocorrea@ufop.edu.br.

ORCID

Daniel P. Bezerra: 0000-0002-6774-2063

Rodrigo S. Correa: 0000-0003-2783-0816

Author Contributions

^{||}D.E.L.C. and K.M.O. contributed equally. The manuscript was written through contributions of all of the authors. All of the authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors would like to thank the financial support of Brazilian Research Agencies: FAPEMIG, FAPESB, FAPESP, CNPq and CAPES. D.E.L.C. thanks FAPEMIG for a fellowship, and K.M.O. is supported by a postdoctoral fellowship grant from CAPES (PNPD program). Also, R.S.C. would like to thank the financial support provided by PROPP/UFOP, FAPEMIG (APQ-01674-18), and CNPq (grants 403588/2016-2 and 308370/2017-1). The authors thank the IFSC-USP (E.E. Castellano and J.A. Ellena) for X-ray crystallography measurements and the "Laboratório Multi-usuário de Caracterização de Moléculas"/UFOP for the NMR facilities.

■ REFERENCES

- (1) Goodgame, M.; Jakubovic, D. A. Metal Complexes of Uracils. *Coord. Chem. Rev.* **1987**, *79*, 97–134.
- (2) Rios, A. C.; Tor, Y. On the Origin of the Canonical Nucleobases: An Assessment of Selection Pressures across Chemical and Early Biological Evolution. *Isr. J. Chem.* **2013**, *53*, 469–483.
- (3) Bhagavan, N. V.; Ha, C.-E. Chapter 25 - Nucleotide Metabolism. In *Essentials of Medical Biochemistry*, 2nd ed.; Bhagavan, N. V.; Ha, C.-E., Eds.; Academic Press: San Diego, 2015; pp 465–487.
- (4) Scofield, M. Nucleic Acids. In *xPharm: The Comprehensive Pharmacology Reference*; Enna, S. J.; Bylund, D. B., Eds.; Elsevier: New York, 2007; pp 1–15.
- (5) Miura, K.; Kinouchi, M.; Ishida, K.; Fujibuchi, W.; Naitoh, T.; Ogawa, H.; Ando, T.; Yazaki, N.; Watanabe, K.; Haneda, S.; et al. 5-FU Metabolism in Cancer and Orally-Administerable 5-FU Drugs. *Cancers* **2010**, *2*, 1717–1730.
- (6) Giacchetti, S.; Perpoint, B.; Zidani, R.; Le Bail, N.; Faggiuolo, R.; Focan, C.; Chollet, P.; Llory, J. F.; Letourneau, Y.; Coudert, B.; et al. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer. *J. Clin. Oncol.* **2000**, *18*, 136.
- (7) Nunes, J. H. B.; Bergamini, F. R. G.; Lustrì, W. R.; de Paiva, P. P.; Ruiz, A. L. T. G.; de Carvalho, J. E.; Corbi, P. P. Synthesis, Characterization and in Vitro Biological Assays of a Silver(I) Complex with 5-Fluorouracil: A Strategy to Overcome Multidrug Resistant Tumor Cells. *J. Fluorine Chem.* **2017**, *195*, 93–101.
- (8) Silva, V. R.; Corrêa, R. S.; de Souza Santos, L.; Soares, M. B. P.; Batista, A. A.; Bezerra, D. P. A Ruthenium-Based 5-Fluorouracil Complex with Enhanced Cytotoxicity and Apoptosis Induction Action in HCT116 Cells. *Sci. Rep.* **2018**, *8*, No. 288.
- (9) Liu, K.-G.; Cai, X.-Q.; Li, X.-C.; Qin, D.-A.; Hu, M.-L. Arene-Ruthenium(II) Complexes Containing 5-Fluorouracil-1-Methyl Isonicotinate: Synthesis and Characterization of Their Anticancer Activity. *Inorg. Chim. Acta* **2012**, *388*, 78–83.
- (10) Kitagawa, S.; Nozaka, Y.; Munakata, M.; Kawata, S. Synthesis and Crystal Structures of Tetra- and Hexanuclear Copper(I) Complexes of Pyrimidine Derivatives, $[\text{Cu}_4(\text{C}_4\text{H}_8\text{N}_2\text{S})_4](\text{ClO}_4)_4$ and $[\text{Cu}_6(\text{C}_5\text{H}_5\text{N}_2\text{S})_6]$. *Inorg. Chim. Acta* **1992**, *197*, 169–175.
- (11) Shaheen, F.; Badashah, A.; Gielen, M.; Marchio, L.; de Vos, D.; Kaleem Khosa, M. Synthesis, Characterization and in Vitro Cytotoxicity of Homobimetallic Complexes of Palladium(II) with 2-

Thiourecil Ligands. Crystal Structure of [Pd₂(TU)(PPh₃)₃Cl₂]. *Appl. Organomet. Chem.* **2007**, *21*, 626–632.

(12) Sce, F.; Beobide, G.; Castillo, O.; de Pedro, I.; Pérez-Yáñez, S.; Reyes, E. Supramolecular Architectures Based on P-Cymene/Ruthenium Complexes Functionalized with Nucleobases. *CrystEngComm* **2017**, *19*, 6039–6048.

(13) Abid, M.; Shamsi, F.; Azam, A. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy. *Mini-Rev. Med. Chem.* **2016**, *772*–786.

(14) Meggers, E. Exploring Biologically Relevant Chemical Space with Metal Complexes. *Curr. Opin. Chem. Biol.* **2007**, *11*, 287–292.

(15) Renfrew, A. K. Transition Metal Complexes with Bioactive Ligands: Mechanisms for Selective Ligand Release and Applications for Drug Delivery. *Metallomics* **2014**, *6*, 1324–1335.

(16) Swaminathan, S.; Haribabu, J.; Kalagatur, N. K.; Konakanchi, R.; Balakrishnan, N.; Bhuvanesh, N.; Karvembu, R. Synthesis and Anticancer Activity of [RuCl₂(H₆-Arene)(Aroylthiourea)] Complexes—High Activity against the Human Neuroblastoma (IMR-32) Cancer Cell Line. *ACS Omega* **2019**, *4*, 6245–6256.

(17) Correa, R. S.; Bomfim, L. M.; Oliveira, K. M.; Moreira, D. R. M.; Soares, M. B. P.; Ellena, J.; Bezerra, D. P.; Batista, A. A. Ru(II) Complexes Containing Uracil Nucleobase Analogs with Cytotoxicity against Tumor Cells. *J. Inorg. Biochem.* **2019**, No. 110751.

(18) Goitia, H.; Villacampa, D. M.; Laguna, A.; Gimeno, C. M. Cytotoxic Gold(I) Complexes with Amidophosphine Ligands Containing Thiophene Moieties. *Inorganics* **2019**, *13*.

(19) Thota, S.; Rodrigues, D. A.; Crans, D. C.; Barreiro, E. J. Ru (II) Compounds: Next-Generation Anticancer Metallotherapeutics? *J. Med. Chem.* **2018**, *61*, 5805–5821.

(20) Trondl, R.; Heffeter, P.; Kowol, C. R.; Jakupec, M. A.; Berger, W.; Keppler, B. K. NKP-1339, the First Ruthenium-Based Anticancer Drug on the Edge to Clinical Application. *Chem. Sci.* **2014**, *5*, 2925–2932.

(21) Kaspler, P.; Lazic, S.; Forward, S.; Arenas, Y.; Mandel, A.; Lilge, L. A Ruthenium(II) Based Photosensitizer and Transferrin Complexes Enhance Photo-Physical Properties, Cell Uptake, and Photodynamic Therapy Safety and Efficacy. *Photochem. Photobiol. Sci.* **2016**, *15*, 481–495.

(22) Mital, M.; Ziora, Z. Biological Applications of Ru(II) Polypyridyl Complexes. *Coord. Chem. Rev.* **2018**, *375*, 434–458.

(23) Renier, O.; Deacon-Price, C.; Peters, E. J.; Nurekeyeva, K.; Russon, C.; Dyson, S.; Ngubane, S.; Baumgartner, J.; Dyson, J. P.; Riedel, T.; et al. Synthesis and In Vitro (Anticancer) Evaluation of H₆-Arene Ruthenium Complexes Bearing Stannyl Ligands. *Inorganics* **2017**, *44*.

(24) Colina-Vegas, L.; Oliveira, K. M.; Cunha, B. N.; Cominetti, M. R.; Navarro, M.; Azevedo Batista, A. Anti-Proliferative and Anti-Migration Activity of Arene–Ruthenium(II) Complexes with Azole Therapeutic Agents. *Inorganics* **2018**, *6*, 132.

(25) Batista, A. A.; Santiago, M. O.; Donnici, C. L.; Moreira, I. S.; Healy, P. C.; Berners-Price, S. J.; Queiroz, S. L. Electrochemical and Spectroscopic Studies on RuCl₂(PPh₃)₂(N)₂ and RuCl₂(PPh₃)₂-(N–N) Complexes (N = pyridine Derivatives and N–N = phenanthroline or Bipyridine Derivatives). X-Ray Structure of RuCl₂(PPh₃)₂(Phen). *Polyhedron* **2001**, *20*, 2123–2128.

(26) Corrêa, R. S.; Da Silva, M. M.; Graminha, A. E.; Meira, C. S.; Dos Santos, J. A. F.; Moreira, D. R. M.; Soares, M. B. P.; Von Poelhsitz, G.; Castellano, E. E.; Bloch, C.; et al. Ruthenium(II) Complexes of 1,3-Thiazolidine-2-Thione: Cytotoxicity against Tumor Cells and Anti-Trypanosoma Cruzi Activity Enhanced upon Combination with Benzimidazole. *J. Inorg. Biochem.* **2016**, *156*, 153–163.

(27) Oliveira, K. M.; Liany, L.-D.; Corrêa, R. S.; Deflon, V. M.; Cominetti, M. R.; Batista, A. A. Selective Ru(II)/Lawson Complexes Inhibiting Tumor Cell Growth by Apoptosis. *J. Inorg. Biochem.* **2017**, *176*, 66–76.

(28) Corrêa, R. S.; da Silva, M. M.; Graminha, A. E.; Meira, C. S.; dos Santos, J. A. F.; Moreira, D. R. M.; Soares, M. B. P.; Von Poelhsitz, G.; Castellano, E. E.; Bloch, C.; et al. Ruthenium(II)

Complexes of 1,3-Thiazolidine-2-Thione: Cytotoxicity against Tumor Cells and Anti-Trypanosoma Cruzi Activity Enhanced upon Combination with Benzimidazole. *J. Inorg. Biochem.* **2016**, *156*, 153–163.

(29) Santos, A. F.; Ferreira, I. P.; Pinheiro, C. B.; Santos, V. G.; Lopes, M. T. P.; Teixeira, L. R.; Rocha, W. R.; Rodrigues, G. L. S.; Beraldo, H. [Ag(L)NO₃] Complexes with 2-Benzoylpyridine-Derived Hydrazones: Cytotoxic Activity and Interaction with Biomolecules. *ACS Omega* **2018**, *3*, 7027–7035.

(30) Zehra, S.; Roisnel, T.; Arjmand, F. Enantiomeric Amino Acid Schiff Base Copper(II) Complexes as a New Class of RNA-Targeted Metallo-Intercalators: Single X-Ray Crystal Structural Details, Comparative In Vitro DNA/RNA Binding Profile, Cleavage, and Cytotoxicity. *ACS Omega* **2019**, *4*, 7691–7705.

(31) Wolfe, A.; Shimer, G. H.; Meehan, T. Polycyclic Aromatic Hydrocarbons Physically Intercalate into Duplex Regions of Denatured DNA. *Biochemistry* **1987**, *26*, 6392–6396.

(32) Ansar Ahmed, S.; Gogal, R. M.; Walsh, J. E. A New Rapid and Simple Non-Radioactive Assay to Monitor and Determine the Proliferation of Lymphocytes: An Alternative to [3H]Thymidine Incorporation Assay. *J. Immunol. Methods* **1994**, *170*, 211–224.

(33) Nicoletti, I.; Migliorati, G.; Pagliacci, M. C.; Grignani, F.; Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. *J. Immunol. Methods* **1991**, *139*, 271–279.